View : 390 Download: 143

Full metadata record

DC Field Value Language
dc.contributor.author장중현-
dc.date.accessioned2016-08-27T04:08:23Z-
dc.date.available2016-08-27T04:08:23Z-
dc.date.issued2015-
dc.identifier.issn1178-2005-
dc.identifier.otherOAK-15865-
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/217737-
dc.description.abstractA new quinolone, zabofloxacin, has now been developed; hence, a non-inferiority trial is needed to compare this new compound with another widely used quinolone to examine its efficacy and safety for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. This was a prospective, multicenter, double-blind, double-dummy, randomized, controlled, parallel-group, Phase III, non-inferiority clinical trial designed to compare oral zabofloxacin (367 mg once daily for 5 days) with moxifloxacin (400 mg once daily for 7 days) for the treatment of patients with COPD exacerbation. In all, 345 COPD patients with a moderate COPD exacerbation were enrolled in the study via the outpatient clinics at 31 university hospitals. Clinical per protocol analysis revealed that the clinical cure rate for zabofloxacin was 86.7% and that for moxifloxacin was 86.3% (the rate difference, 0.4%; 95% confidence interval, -7.7%-8.6%). Intention-to-treat analysis revealed clinical cure rates of 77.1% and 77.3% (difference, -0.2%; 95% confidence interval, -9.0%-8.8%), respectively. These results confirm that zabofloxacin is not inferior to moxifloxacin. The favorable microbiological response rate for zabofloxacin was 67.4% and that for moxifloxacin was 79.5% (P=0.22). Patients in the zabofloxacin group showed better patient-oriented outcomes, as measured by EXAcerbations of Chronic Pulmonary Disease Tool-Patient-Reported Outcome and the COPD assessment test scores, than patients in the moxifloxacin group. Adverse drug reactions related to zabofloxacin occurred in 9.7% of cases and those related to moxifloxacin occurred in 9.6% of cases (P=0.97). The dropout rate due to adverse events was 0% (0/175) in the zabofloxacin group and 1.8% (3/167) in the moxifloxacin group (P=0.12). Oral zabofloxacin (367 mg once daily for 5 days) was not inferior to oral moxifloxacin (400 mg once daily for 7 days) for the treatment of patients with COPD exacerbation.-
dc.languageEnglish-
dc.publisherDOVE MEDICAL PRESS LTD-
dc.subjectchronic obstructive pulmonary disease-
dc.subjectexacerbation-
dc.subjectzabofloxacin-
dc.subjectquinolone-
dc.subjectEXACT-PRO-
dc.subjectCAT-
dc.titleZabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial-
dc.typeArticle-
dc.relation.volume10-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.journaltitleINTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE-
dc.identifier.doi10.2147/COPD.S90948-
dc.identifier.wosidWOS:000363186500001-
dc.identifier.scopusid2-s2.0-84945551240-
dc.author.googleRhee, Chin Kook-
dc.author.googleChang, Jung Hyun-
dc.author.googleChoi, Eu Gene-
dc.author.googleKim, Hyun Kuk-
dc.author.googleKwon, Yong-Soo-
dc.author.googleKyung, Sun Young-
dc.author.googleLee, Ji-Hyun-
dc.author.googlePark, Myung Jae-
dc.author.googleYoo, Kwang Ha-
dc.author.googleOh, Yeon Mok-
dc.contributor.scopusid장중현(57193227620;8984470200)-
dc.date.modifydate20210915112853-
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
001.pdf(1.02 MB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE